Fabiana Perna is an Oncology physician affiliated with Moffitt Cancer Center. OpenAlex indexes 199 publications with 6,887 citations (h-index 29).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year20241 payment
- AstraZeneca Pharmaceuticals LPProgram year20234 payments
- Celgene CorporationProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
100%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor100%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2023–2026 per NIH RePORTER. The latest:
- Identifying cell surface targets for innovative immunotherapy of Multiple Myeloma
H. Lee Moffitt Cancer Ctr & Res Inst
FY2026$669,302R37CA276939 - Identifying cell surface targets for innovative immunotherapy of Multiple Myeloma
H. Lee Moffitt Cancer Ctr & Res Inst
FY2025$507,197R37CA276939 - Identifying cell surface targets for innovative immunotherapy of Multiple Myeloma
H. Lee Moffitt Cancer Ctr & Res Inst
FY2024$528,175R37CA276939
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Clinical Cancer Research
2025 - Mapping the cancer surface proteome in search of target antigens for immunotherapy
Molecular Therapy
2024 - Translation efficiency driven by CNOT3 subunit of the CCR4-NOT complex promotes leukemogenesis
Nature Communications
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Ignacio Wistuba, MD
Moffitt Cancer Center
Christine Chung, MD
Moffitt Cancer Center
Jonathan Strosberg, MD
Moffitt Cancer Center
Nikhil Khushalani, MD
Moffitt Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”